The foundation of our transdermal business was established through strong partnerships.
Corium has demonstrated a strong track record of developing complex transdermal products for partners and manufacturing them for clinical development and commercial sale. Today, we have built on this foundation to create a balanced business model, allowing us to build a high-value proprietary CNS pipeline while continuing to create value for existing and new partners.
Corium’s two lead proprietary product candidates are focused on the treatment of Alzheimer’s disease:
Proprietary Pipeline
| PRODUCT | APPLICATION | STATUS |
| Corplex Donepezil | Alzheimer’s Disease | Pilot BE |
| Corplex Memantine | Alzheimer’s Disease | Phase 1 |
| Corplex Ropinirole | Parkinson’s Disease | Preclinical |
| MicroCor hPTH(1-34) | Osteoporosis | Phase 2 |
| MicroCor Zolmitriptan | Acute Migraine | Preclinical |
Our partnered programs include commercial and development-stage transdermal product opportunities:
Partnered Pipeline
| SPONSOR | PRODUCT | APPLICATION | STATUS |
 |
Clonidine TDS | Hypertension | Marketed |
|
Fentanyl TDS | Pain | Marketed |
 |
Crest® Whitestrips (5 Products) | Teeth Whitening | Marketed |
 |
Twirla® | Contraception | Phase 3 |
|
Undisclosed | Motion Sickness | ANDA Filed |
 |
Aripiprazole | Schizophrenia | Phase 1 |